A Review of Momordica charantia L., Botanical Characteristics, Nutritional Properties, and Bioactive Compounds: Insights for Type 2 Diabetes Mellitus
Article Sidebar
Main Article Content
Abstract
The prevalence of metabolic disorders, particularly Type 2 Diabetes Mellitus (T2DM), is rising at an alarming rate worldwide. T2DM, a complex metabolic condition characterized by hyperglycemia and glucose intolerance, remains one of the most common metabolic disorders, posing significant challenges to global healthcare systems. Traditional medicine serves as a valuable complementary approach alongside conventional therapies in managing T2DM. Momordica charantia L. (MC), commonly used in traditional medicine for its glucose-lowering properties, is also consumed as a dietary component in regions such as Asia, South America, and East Africa, with extensive use in Vietnam. Recognised as a functional herb with a history spanning thousands of years, MC is rich in antioxidants and anti-inflammatory compounds, which show potential for the prevention and treatment of T2DM. This review focuses on the botanical characteristics of MC and examines evidence from in vitro, in vivo, and clinical studies. These findings collectively suggest the promising efficacy of MC in T2DM management. Preclinical studies have demonstrated its beneficial effects through multiple mechanisms, including reducing hyperglycemia and enhancing insulin secretion, mediated by its bioactive compounds. Some clinical studies have also shown its anti-hyperglycemic effects. However, further research is necessary to validate its clinical effectiveness and establish its definitive role in supporting T2DM management.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
1. Lancet T. Diabetes: a defining disease of the 21st century. The Lancet. 2023;401(10394):2087.
2. Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, Shaw JE, Paciorek CJ, Singleton RK, Pires AB, Stevens GA. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet. 2024;404(10467):2077–2093.
3. Tran VD, Tran VD, Pham DT, Nguyen NNL, Le ND, Dao TNP. Perspectives on COVID-19 prevention and treatment using herbal medicine in Vietnam: A cross-sectional study. Ann Ig. 2022;34(5):515–531.
4. Fokunang C, Ndikum V, Tabi O, Jiofack R, Ngameni B. Traditional Medicine: Past, Present and Future Research and Development Prospects and Integration in the National Health System of Cameroon. Afr J Tradit Complement Altern Med. 2011;8(3):284–295.
5. Le MH, Sam HS, Pham DT, Nguyen NCL, Le ND, Dao TNP. Ngu-Vi-Tieu-Khat decoction, a Vietnamese traditional medicine, possesses hypoglycemic and hypolipidemic effects on streptozotocin-induced type-2 diabetic rat model. Pharmacia. 2023;70(4):943–950.
6. Chetty L, Govender N, Reddy P. Traditional Medicine Use among Type 2 Diabetes Patients in KZN. Adv. Public Health. 2022; (1):7334080.
7. Sriraman S, Sreejith D, Andrew E, Okello I, Willcox M. Use of herbal medicines for the management of type 2 diabetes: A systematic
review of qualitative studies. Complement Ther Clin Pract. 2023;53:101808.
8. Lema GD, Gebeyaw ED, Yferu ZA, Mulatu SF, Dagnaw AB, Aydagnuhm GB, Ayicheh EA. Herbal medicine use and its impact on glycemic control among diabetes patients at governmental hospitals in Debre Berhan, Ethiopia: A cross-sectional study. Metabolism Open. 2024;23:100311.
9. MCBenedict B, Orfao AL, Goh KS, Yau RCC, Alphonse B. The Role of Alternative Medicine in Managing Type 2 Diabetes: A Comprehensive Review. Cureus. 2024;16(6):e61965.
10. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3(2):93–102.
11. Van Chi V. Dictionary of Medicinal Plants in Vietnam. Ha Noi: Medicine Publisher; 1997.
12. Do TL. Medicinal Plants and Materia Medica of Vietnam. Hanoi, Vietnam: Medical Publishing House; 2003.
13. Pham HH. An Illustrated Flora of Vietnam. Tre Publishing House; 1991.
14. Sheikh HI, Zakaria NH, Abdul Majid FA, Zamzuri F, Fadhlina A, Hairani MAS. Promising roles of Zingiber officinale roscoe, Curcuma longa L., and Momordica charantia L. as immunity modulators against COVID-19: A bibliometric analysis. J Agric Food Res. 2023;14:100680.
15. Raina K, Kumar D, Agarwal R. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy. Semin Cancer Biol. 2016;40–41:116–129.
16. Ngoc VTB, Vi LTT, Trinh TT, Ha LHH, Em PC. Evaluation of the Antimicrobial and Antifungal Activities of Bitter Melon Fruit Extract (Momordica charantia L. Var. Abbreviata Ser.) harvested in Ben Tre Province, Vietnam. HIUJS. 2023;43–50. (in Vietnamese)
17. Yue J, Sun Y, Xu J, Cao J, Chen G, Zhang H, Zhang X, Zhao Y. Cucurbitane triterpenoids from the fruit of Momordica charantia L. and their anti-hepatic fibrosis and anti-hepatoma activities. Phytochemistry. 2019;157:21–27.
18. Jia S, Shen M, Zhang F, Xie J. Recent Advances in Momordica charantia: Functional Components and Biological Activities. Int J Mol Sci. 2017;18(12):2555.
19. Chan EWC. A Mini-Review on the Neuroprotective Effects of Extracts and Metabolites of Momordica charantia. Trop. J. Nat. Prod. Res. 2024;8(1):5727–5733.
20. Prasesti GK, Anggadiredja K, Kurniati NF. Momordica charantia Fruit Extract on Cardiac Biomarker Serum Attenuation in Rats and its Bioactive Compound Molecular Docking Against SIRT-1 Protein. Trop. J. Nat. Prod. Res.. 2023;7(1):2229–2233.
21. Romdhoni MF, Doewes M, Soetrisno S, Febrinasari RP. In vivo Effect of Momordica charantia on Dipeptidyl Peptidase-4 Activity in Diabetic Rats. Trop. J. Nat. Prod. Res. 2024;8(12):9560–9563.
22. Janagal B, Singh C, Purvia RP, Adlakha M. A review of hypoglycemic effect of Momordica charantia w.s.r. to madhumeh. Int. J. Ayurveda
Pharma Res. 2018; 6(1):50-54.
23. Liaw CC, Huang HT, Liu HK, Lin YC, Zhang LJ, Wei WC, Shen CC, Wu CL, Huang CY, Kuo YH. Cucurbitane-type triterpenoids from the vines
of Momordica charantia and their anti-inflammatory, cytotoxic, and antidiabetic activity. Phytochem. 2022;195:113026.
24. Innih SO, Eze IG, Omage K. Cardiovascular benefits of Momordica charantia in cholesterol-fed Wistar rats. Clinical Phytoscience. 2021;7(1):65.
25. Joshi A, Soni P, Malviya S, Kharia A. Memory enhancing activity of Momordica charantia by scopolamine induced amnesia in rats. Indian J Clin Anat Physiol. 2017; 2(1):11–18.
26. Muribeca A de JB, Gomes PWP, Paes SS, da Costa APA, Gomes, PWP, Viana JdS, Reis JDE, Pamplona, SdG, Silva C, Bauermeister A, Santos LdS, da Silva MN. Antibacterial Activity from Momordica charantia L. Leaves and Flavones Enriched Phase. Pharmaceutics. 2022;14(9):1796.
27. Doğaroğlu ZG, Uysal Y, Çaylalı Z, Karakoç G. Antibacterial and phytotoxicological properties assessment of extract-based ZnO nanoparticles. J Sci Food Agric. 2024;104(5):2851–2861.
28. Jat GS, Behera TK, Singh AK, Bana RS, Singh D, Godara S, Reddy UK, Rao PG, Ram H, Vinay ND, Kumar S, Tomar BS. Antioxidant activities, dietary nutrients, and yield potential of bitter gourd (Momordica charantia L.) lines in diverse growing environments. Front Nutr. 2024;11.
29. Ciou SY, Hsu CC, Kuo YH, Chao CY. Effect of wild bitter gourd treatment on inflammatory responses in BALB/c mice with sepsis. Biomedicine. 2014;4(3):17.
30. Wang D, Wang E, Li Y, Teng Y, Li H, Jiao L, Wu W. Anti-Aging Effect of Momordica charantia L. on d-Galactose-Induced Subacute Aging in Mice by Activating PI3K/AKT Signaling Pathway. Molecules. 2022;27(14):4502.
31. Aeri V, Raj R. Medicinal Properties of Bitter Gourd: Bioactives and Their Actions. Cham: Springer International Publishing; 2020; 33–44.
32. Gayathry KS, John JA. A comprehensive review on bitter gourd (Momordica charantia L.) as a gold mine of functional bioactive components for therapeutic foods. Food Prod. Process. Nutr.. 2022;4(1):10.
33. Mai ĐV, Thu ĐLA, Sanda TMB, Truc ĐT. Survey of botanical characteristics and preliminary chemical composition of forest bitter melon (Momordica charantia L.) grown in An Giang. JSDE. 2024;(27):3–12. (in Vietnamese)
34. Richter E, Geetha T, Burnett D, Broderick TL, Babu JR. The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer’s Disease. Int J Mol Sci. 2023;24(5):4643.
35. Snee LS, Nerurkar VR, Dooley DA, Efird JT, Shovic AC, Nerurkar PV. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): A vegetable commonly used for diabetes management. Nut J. 2011;10(1):78.
36. Xu B, Li Z, Zeng T, Zhan JF, Wang SZ, Ho CT, Li SM. Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents. Molecules 2022;27(7):2175.
37. Mahmoud MF, Hassan NA, El Bassossy HM, Fahmy A. Quercetin protects against diabetes-induced exaggerated vasoconstriction in rats: effect on low-grade inflammation. PLoS One. 2013;8(5):e63784.
38. Dung TTT, Tri NM. Biochemical compositions, antioxidant activity, and in vitro antibacterial activity of extract from wild bitter melon (Momordica charantia var. abbreviata Ser.). VJFC. 2021;4(2):109–114.
39. Iseli TJ, Turner N, Zeng XY, Cooney GJ, Kraegen EW, Yao S, Ye Y, James DE, Ye JM. Activation of AMPK by bitter melon triterpenoids involves CaMKKβ. PLoS One. 2013;8(4):e62309.
40. Keller AC, Ma J, Kavalier A, He K, Brillantes AMB, Kennelly EJ. Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro. Phytomedicine. 2011;19(1):32–37.
41. Harinantenaina L, Tanaka M, Takaoka S, Oda M, Mogami O, Uchida M, Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo). 2006;54(7):1017–1021.
42. Iwansyah AC, Luthfiyanti R, Ardiansyah RCE, Rahman N, Andriana Y, Hamid HA. Antidiabetic activity of Physalis angulata L. fruit juice on streptozotocin-induced diabetic rats. S Afr J Bot. 2022;145:313–319.
43. Ali L, Khan AK, Mamun MI, Mosihuzzaman M, Nahar N, Nure-Alam M, Rokeya B. Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med. 1993;59(5):408–412.
44. Sarkar S, Pranava M, Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res. 1996;33(1):1–4.
45. Yibchok-anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow-acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 2006;29(6):1126–1131.
46. Singh N, Gupta M. Regeneration of beta cells in islets of Langerhans of pancreas of alloxan diabetic rats by acetone extract of Momordica charantia (Linn.) (bitter gourd) fruits. Indian J Exp Biol. 2007;45(12):1055–1062.
47. Saha SK, Haque ME, Islam D, Rahman MM, Islam MR, Parvin A, Rahman S. Comparative study between the effect of Momordica charantia (wild and hybrid variety) on hypoglycemic and hypolipidemic activity of alloxan-induced type 2 diabetic long-Evans rats. J. Diab.
Mell. 2012;2(1):131–137.
48. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr. 2008;99(4):806–812.
49. Chen Q, Chan LLY, Li ETS. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high-fat diet. J Nutr. 2003;133(4):1088–1093.
50. França EL, Ribeiro EB, Scherer EF, Cantarini DG, Pessoa RS, Franca FL, Honorio FA. Effects of Momordica charantia L. on the Blood Rheological Properties in Diabetic Patients. Biomed Res. Int 2014;2014(1):840379.
51. Welihinda J, Karunanayake EH, Sheriff MHH, Jayasinghe KSA. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J. Ethnopharmacol. 1986;17(3):277–282.
52. Peter EL, Kasali FM, Deyno S, Mtewa A, Nagendrappa PB, Tolo CU, Ogwang PE, Sesaazi D. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. J. Ethnopharmacol. 2019;231:311–324.
53. Zhang X, Zhao Y, Song Y, Miao M. Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials. Heliyon. 2024;10(10):e31126